SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-003531
Filing Date
2024-05-15
Accepted
2024-05-15 17:00:33
Documents
43
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR 3/31/24 cns_i10q-033124.htm   iXBRL 10-Q 425989
2 CERTIFICATION BY CHIEF EXECUTIVE OFFICER cns_ex3101.htm EX-31.1 6834
3 CERTIFICATION BY CHIEF FINANCIAL OFFICER cns_ex3102.htm EX-31.2 6880
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3201.htm EX-32.1 3205
5 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3202.htm EX-32.2 3271
  Complete submission text file 0001683168-24-003531.txt   2913734

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20240331.xsd EX-101.SCH 22279
7 XBRL CALCULATION FILE cnsp-20240331_cal.xml EX-101.CAL 24830
8 XBRL DEFINITION FILE cnsp-20240331_def.xml EX-101.DEF 114044
9 XBRL LABEL FILE cnsp-20240331_lab.xml EX-101.LAB 262976
10 XBRL PRESENTATION FILE cnsp-20240331_pre.xml EX-101.PRE 213961
46 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-033124_htm.xml XML 271001
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 24952291
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)